Generic name: talquetamab-tgvs
Used for: Multiple myeloma
Ask for the cash price
Talvey
Talvey is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.
Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program. Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL).
Or call 1-833-742-0791.
Details for each option
Savings card from Johnson & Johnson (Janssen)
Or call 1-833-565-9631.
“Eligible patients pay $5 for each dose.”
From the maker’s offer on jnjwithme.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.
Optum Perks, Optum’s free discount coupon, lists these prices for Talvey without insurance. Show the coupon from its page at the pharmacy; it can’t be used with insurance.
From Optum Perks, read November 2, 2026, with no location set. Its page opens on this dose; other doses and pharmacies near you are priced there too. With insurance, check your co-pay first: it may be lower.
There isn’t one. An authorized generic is Talvey itself, from the same company, sold without the brand name, and usually for less. For now Talvey is the only choice; its maker’s savings card can lower what you pay.
Talvey is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.
TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Source: the FDA label for Talvey (Janssen Biotech, Inc.), October 8, 2025. Full label on DailyMed
Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/talvey/